We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Cisbio and Lumiphore Announce Partnership for new Product and Technology Development

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cisbio and Lumiphore Announce Partnership for new Product and Technology Development"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Cisbio and Lumiphore, Inc. announced that they have signed an exclusive agreement for the incorporation of Lumiphore’s Lumi4™ complexes in Cisbio assays.

Under the agreement, Cisbio holds the exclusive rights to apply Lumi4™ technology to current and future research and development initiatives in TR-FRET-based (Time-Resolved Fluorescence Resonance Energy Transfer) assays for drug discovery.

Lumi4™ compounds bring photophysical properties, increased sensitivity and stability to TR-FRET assays for high-throughput screening (HTS) applications and the growing homogeneous assay market.

The incorporation of Lumi4™ compounds to Cisbio’s proprietary HTRF® technology has the potential to enable the development of a second generation of assay platforms used in HTS, particularly in the fields of GPCR (G-Protein Coupled Receptors) and kinase screening.

Combining the two technologies will allow for the development of new HTRF® applications and increased possibilities for HTS implementation of Cisbio’s assays.